<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01344330</url>
  </required_header>
  <id_info>
    <org_study_id>P01CA090890</org_study_id>
    <secondary_id>P01CA090890</secondary_id>
    <nct_id>NCT01344330</nct_id>
  </id_info>
  <brief_title>Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients</brief_title>
  <official_title>Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas A&amp;M University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will assess cruciferous vegetable intake in patients presenting for&#xD;
      screening colonoscopy and correlate intake with histone status and histone deacetylace (HDAC)&#xD;
      expression in tissue biopsy specimens and peripheral blood mononuclear cells (PBMCs). The&#xD;
      investigators will also measure sulforaphane (SFN) metabolites in blood as a biomarker of&#xD;
      cruciferous vegetable intake.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cruciferous vegetable intake correlated with SFN and I3C urinary metabolites</measure>
    <time_frame>At colonoscopy (day 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cruciferous vegetable intake and p21 expression (qRT-PCR, ChIP in PBMCs)</measure>
    <time_frame>at colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cruciferous vegetable intake correlated with acetylated histone expression (PBMCs, colon tissue),</measure>
    <time_frame>at colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cruciferous vegetable intake correlated with HDAC activity (in PBMCs)</measure>
    <time_frame>at colonoscopy</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">108</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Screening colonoscopy patients</arm_group_label>
    <description>Men and women age 50 to 75 scheduled for screening colonoscopy</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Protein lysate and RNA obtained from de-identified normal colon biopsy specimens are stored&#xD;
      at -80 degree centigrade.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for screening colonoscopy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  scheduled for screening colonoscopy&#xD;
&#xD;
          -  off NSAID or aspirin therapy in accordance with OHSU endoscopy clinic guidelines&#xD;
&#xD;
          -  INR 0.90-1.20&#xD;
&#xD;
          -  hemoglobin ≥ 13.5 (men) or 12.0 (women)&#xD;
&#xD;
          -  platelets ≥100,000/μL&#xD;
&#xD;
          -  Chem screen results within normal limits&#xD;
&#xD;
          -  negative (serum or urine) pregnancy test done ≤7 days prior to colonoscopy for women&#xD;
             of childbearing potential only&#xD;
&#xD;
          -  ASA performance status &lt;2&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  history of colon cancer or adenomatous polyps&#xD;
&#xD;
          -  current smoker&#xD;
&#xD;
          -  medical history of chronic obstructive pulmonary disease&#xD;
&#xD;
          -  current oral steroid therapy&#xD;
&#xD;
          -  current therapy with valproate or other pharmacological drugs associated with HDAC&#xD;
             inhibition&#xD;
&#xD;
          -  use of oral antibiotics within 3 months prior to entry into study&#xD;
&#xD;
          -  significant active medical illness which in the opinion of the investigator would&#xD;
             preclude collection/interpretation of colon tissue&#xD;
&#xD;
          -  diagnosis of hemophilia, van Willebrand's disease or other bleeding disorder&#xD;
&#xD;
          -  use of warfarin or other blood thinning agents&#xD;
&#xD;
          -  inflammatory bowel disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rod Dashwood, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 27, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2011</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas A&amp;M University</investigator_affiliation>
    <investigator_full_name>Roderick Dashwood</investigator_full_name>
    <investigator_title>Professor, Texas A&amp;M HSC</investigator_title>
  </responsible_party>
  <keyword>Colon cancer</keyword>
  <keyword>Prevention</keyword>
  <keyword>Cruciferous vegetables</keyword>
  <keyword>Histone status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Group information (High versus Low Cruciferous Vegetable Intake) will be made available. No IPD will be made available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

